Cyrille K. Cornelio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cyrille K. Cornelio has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Nicholas C. Schwier
NYU Langone Hospital - Long Island, Department of Pharmacy, New York, United States of America
2 shared publications - Raechel T. White
USF Taneja College of Pharmacy, University of South Florida Tampa Florida USA
2 shared publications Aimon C. Miranda
Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, University of South Florida Health, Tampa, FL, USA
1 shared publication- Aimon C. Miranda
Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy University of South Florida Tampa Florida USA
1 shared publication Andrew J. Smith
School of Pharmacy, University of Missouri Kansas City, Kansas City, MO, USA
1 shared publicationAnh T. Phan
Department of Pharmacy, Michigan Medicine University of Michigan Ann Arbor Michigan USA
1 shared publication
Latest Publications
- 9 March 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (4) , e70130
Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
Introduction: The cardiovascular (CV) benefits of glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) therapies are not well‐established in women with breast cancer and type 2 diabetes (T2D). Objectives: The primary objective of this study was to compare the incidence of major adverse cardiovascular events (MACE) in women with T2D and breast cancer receiving GLP‐1 RA therapy versus non‐GLP‐1 RA diabetes medications. Methods: This retrospective study included women with T2D, diagnosed with breast cancer at ≥ 40 years old from December 16, 2014 to December 16, 2024 and having exposure to diabetes medications of interest (either GLP‐1 RA or non‐GLP‐1 RA) within 5 years of these diagnoses. The primary end point, MACE, was a composite of myocardial infarction, ischemic stroke, coronary revascularization, cardiac arrest, or heart failure, within 5 years of the index date. Propensity score matching was performed. Participants were excluded from each individual outcome analysis if they had the outcome prior to the index date. Incidence rates, risk ratio (RR), 95% confidence interval (CI), and p ‐value were reported for each outcome. Results: After matching, 19,608 patients were included in each cohort (mean age 64 years). Obesity and alkylating agents were more commonly reported in the GLP‐1 RA cohort. Semaglutide was the most prescribed GLP‐1 RA at index (45.1%). MACE occurred in 10.6% of the GLP‐1 RA cohort and 13.4% of the non‐GLP‐1 cohort (RR 0.80, 95% CI 0.75–0.85, p < 0.001). Individual MACE end points, ischemic heart disease, and end‐stage renal disease were significantly lower in the GLP‐1 RA‐treated cohort. GLP‐1 RA use was also associated with a 61.6% relative risk reduction in all‐cause mortality (RR 0.38, 95% CI 0.36–0.41, p < 0.001). Pancreatitis incidence was similar between groups ( p = 0.057), whereas cholelithiasis was significantly lower with GLP‐1 RA therapy ( p < 0.001). Conclusions: This study demonstrated the potential CV benefit of GLP‐1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.
- 9 March 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (4) , e70130
Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
Introduction: The cardiovascular (CV) benefits of glucagon‐like‐peptide‐1 receptor agonist (GLP‐1 RA) therapies are not well‐established in women with breast cancer and type 2 diabetes (T2D). Objectives: The primary objective of this study was to compare the incidence of major adverse cardiovascular events (MACE) in women with T2D and breast cancer receiving GLP‐1 RA therapy versus non‐GLP‐1 RA diabetes medications. Methods: This retrospective study included women with T2D, diagnosed with breast cancer at ≥ 40 years old from December 16, 2014 to December 16, 2024 and having exposure to diabetes medications of interest (either GLP‐1 RA or non‐GLP‐1 RA) within 5 years of these diagnoses. The primary end point, MACE, was a composite of myocardial infarction, ischemic stroke, coronary revascularization, cardiac arrest, or heart failure, within 5 years of the index date. Propensity score matching was performed. Participants were excluded from each individual outcome analysis if they had the outcome prior to the index date. Incidence rates, risk ratio (RR), 95% confidence interval (CI), and p ‐value were reported for each outcome. Results: After matching, 19,608 patients were included in each cohort (mean age 64 years). Obesity and alkylating agents were more commonly reported in the GLP‐1 RA cohort. Semaglutide was the most prescribed GLP‐1 RA at index (45.1%). MACE occurred in 10.6% of the GLP‐1 RA cohort and 13.4% of the non‐GLP‐1 cohort (RR 0.80, 95% CI 0.75–0.85, p < 0.001). Individual MACE end points, ischemic heart disease, and end‐stage renal disease were significantly lower in the GLP‐1 RA‐treated cohort. GLP‐1 RA use was also associated with a 61.6% relative risk reduction in all‐cause mortality (RR 0.38, 95% CI 0.36–0.41, p < 0.001). Pancreatitis incidence was similar between groups ( p = 0.057), whereas cholelithiasis was significantly lower with GLP‐1 RA therapy ( p < 0.001). Conclusions: This study demonstrated the potential CV benefit of GLP‐1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.
- 11 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 84
Prevalence of statin utilization in cancer survivors in a family medicine clinic
Purpose As people live longer after a cancer diagnosis, there is an increasing need to focus on chronic disease state management in the primary care setting. Particular attention to appropriate statin prescribing in cancer survivors is warranted given a heightened risk of atherosclerotic cardiovascular disease (ASCVD). The purpose of this study was to further understand cardiovascular care in cancer survivors by identifying the proportion of cancer survivors with a prescription for appropriate statin therapy and to identify associated factors. Methods A retrospective cohort study was conducted to identify cancer survivors aged 40–75 years with a diagnosis of breast, lung, colorectal, or lymphatic and hematopoietic cancers cared for within family medicine clinics in a large academic health system. Statin prescriptions were assessed to identify the percentage of statin candidates prescribed a statin based on a diagnosis of ASCVD or type 2 diabetes. Results Data from 8763 cancer survivors were included in the final analysis. Among patients with ASCVD, 66% were prescribed a statin. In patients with type 2 diabetes without ASCVD, 58% were prescribed a statin. Female sex was negatively associated with statin prescribing (OR 0.88, 95% CI 0.80–0.97). Conclusions Statins are underutilized in cancer survivors, as they are in the general population. This may present an area of health disparity given the heightened risk of ASCVD in cancer survivors. Cancer survivors suffer from a heightened risk of death from CVD. As survivors enjoy longer lifespans after diagnosis, there is a need to optimize cardiometabolic disease state management in this high-risk population.
- 11 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 84
Prevalence of statin utilization in cancer survivors in a family medicine clinic
Purpose As people live longer after a cancer diagnosis, there is an increasing need to focus on chronic disease state management in the primary care setting. Particular attention to appropriate statin prescribing in cancer survivors is warranted given a heightened risk of atherosclerotic cardiovascular disease (ASCVD). The purpose of this study was to further understand cardiovascular care in cancer survivors by identifying the proportion of cancer survivors with a prescription for appropriate statin therapy and to identify associated factors. Methods A retrospective cohort study was conducted to identify cancer survivors aged 40–75 years with a diagnosis of breast, lung, colorectal, or lymphatic and hematopoietic cancers cared for within family medicine clinics in a large academic health system. Statin prescriptions were assessed to identify the percentage of statin candidates prescribed a statin based on a diagnosis of ASCVD or type 2 diabetes. Results Data from 8763 cancer survivors were included in the final analysis. Among patients with ASCVD, 66% were prescribed a statin. In patients with type 2 diabetes without ASCVD, 58% were prescribed a statin. Female sex was negatively associated with statin prescribing (OR 0.88, 95% CI 0.80–0.97). Conclusions Statins are underutilized in cancer survivors, as they are in the general population. This may present an area of health disparity given the heightened risk of ASCVD in cancer survivors. Cancer survivors suffer from a heightened risk of death from CVD. As survivors enjoy longer lifespans after diagnosis, there is a need to optimize cardiometabolic disease state management in this high-risk population.
- 22 February 2025
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 41 (3) , 134-143
Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
Objective: The objective of the study is to review the characteristics, efficacy, safety, and clinical relevance of sotatercept in pulmonary arterial hypertension (PAH). Data Sources: A literature search containing search terms related to sotatercept and PAH was conducted. Embase via Elsevier, MEDLINE via Ovid, the medRxiv preprint server, Cochrane Library CENTRAL trials registry, and ClinicalTrials.gov were searched from inception through October 31, 2024. The package insert was utilized to obtain drug information and additional data. Study Selection and Data Extraction: Phase II-III clinical trials investigating sotatercept for PAH were included. Articles written in English were extracted while animal studies and phase I clinical trials were excluded. Data Synthesis: In patients with WHO Group 1, functional class II-III PAH, adding sotatercept to background therapy increased 6-minute walk distance in phase II-III trials. Pooled analysis from PULSAR (phase II) and STELLAR (phase III) showed improvements in pulmonary vascular resistance and NT-proBNP. Exploratory data from PULSAR revealed that BMPR2 genetic variant status was not associated with significant differences in treatment effects. SPECTRA (phase IIb) demonstrated improved right ventricular structure and function. Interim analysis from SOTERIA showed that treatment effects persist at 1 year. Conclusions: Sotatercept is a viable add-on therapy for patients with PAH Group 1 and functional class II-III. Additional data are needed to assess long-term outcomes among treatment-naïve patients and those with the most severe symptomatology.
- 22 February 2025
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 41 (3) , 134-143
Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension
Objective: The objective of the study is to review the characteristics, efficacy, safety, and clinical relevance of sotatercept in pulmonary arterial hypertension (PAH). Data Sources: A literature search containing search terms related to sotatercept and PAH was conducted. Embase via Elsevier, MEDLINE via Ovid, the medRxiv preprint server, Cochrane Library CENTRAL trials registry, and ClinicalTrials.gov were searched from inception through October 31, 2024. The package insert was utilized to obtain drug information and additional data. Study Selection and Data Extraction: Phase II-III clinical trials investigating sotatercept for PAH were included. Articles written in English were extracted while animal studies and phase I clinical trials were excluded. Data Synthesis: In patients with WHO Group 1, functional class II-III PAH, adding sotatercept to background therapy increased 6-minute walk distance in phase II-III trials. Pooled analysis from PULSAR (phase II) and STELLAR (phase III) showed improvements in pulmonary vascular resistance and NT-proBNP. Exploratory data from PULSAR revealed that BMPR2 genetic variant status was not associated with significant differences in treatment effects. SPECTRA (phase IIb) demonstrated improved right ventricular structure and function. Interim analysis from SOTERIA showed that treatment effects persist at 1 year. Conclusions: Sotatercept is a viable add-on therapy for patients with PAH Group 1 and functional class II-III. Additional data are needed to assess long-term outcomes among treatment-naïve patients and those with the most severe symptomatology.
- 12 June 2023
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (3) , 786-799
Key Articles and Guidelines in the Management of Pericardial Syndromes
Over the past two decades, emerging literature has shaped the management of pericardial syndromes and has evolved abundantly towards the creation of European guidelines for the diagnosis and management of pericardial diseases. However, since the publication of the European guidelines in 2015, more data surrounding the management of pericardial syndromes have been published. Comprehensive reference materials with the most updated literature are warranted and can be pivotal in helping pharmacists make evidence-based and clinical decisions for patients diagnosed with pericardial syndromes. This compilation of key articles and guidelines will serve as a resource for pharmacists who are responsible for the care of patients with pericardial syndromes.
- 12 June 2023
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 37 (3) , 786-799
Key Articles and Guidelines in the Management of Pericardial Syndromes
Over the past two decades, emerging literature has shaped the management of pericardial syndromes and has evolved abundantly towards the creation of European guidelines for the diagnosis and management of pericardial diseases. However, since the publication of the European guidelines in 2015, more data surrounding the management of pericardial syndromes have been published. Comprehensive reference materials with the most updated literature are warranted and can be pivotal in helping pharmacists make evidence-based and clinical decisions for patients diagnosed with pericardial syndromes. This compilation of key articles and guidelines will serve as a resource for pharmacists who are responsible for the care of patients with pericardial syndromes.
- 30 August 2022
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 38 (6) , 368-373
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Objective: To review clinical data regarding the newly approved drug setmelanotide, an injectable melanocortin 4 receptor (MC4R) agonist, for chronic weight management in adults and children aged 6 years and older with monogenic obesity. Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles published between January 1, 1996, and November 30, 2021, using search terms obesity, setmelanotide, Imcivree, and MC4R agonist. Study Selection/Data Extraction: This review included two phase 2, two phase 3, and one ongoing clinical trial evaluating the efficacy and/or safety of setmelanotide. Data Synthesis: Setmelanotide demonstrates statistically significant weight loss with at least a 10% decrease in body weight after 1 year and decreased appetite in phase 2 and phase 3 clinical trials. The most common adverse effects included injection site reaction (96%), skin hyperpigmentation (78%), nausea (56%), headache (41%), and diarrhea (37%). Place in Therapy: Setmelanotide is the first and only Food and Drug Administration–approved medication for the treatment of proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, and leptin receptor deficiency in patients with obesity. It may be used in children and adults who have received genetic testing and exhibited extreme obesity before age five. Setmelanotide is a daily subcutaneous injection and may be difficult to afford for patients. Conclusion: Setmelanotide is an effective treatment in patients with obesity and indicated genetic disorders.
- 30 August 2022
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 38 (6) , 368-373
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Objective: To review clinical data regarding the newly approved drug setmelanotide, an injectable melanocortin 4 receptor (MC4R) agonist, for chronic weight management in adults and children aged 6 years and older with monogenic obesity. Data Sources: A literature review was performed by searching MEDLINE, SCOPUS, and EMBASE for all relevant English-language articles published between January 1, 1996, and November 30, 2021, using search terms obesity, setmelanotide, Imcivree, and MC4R agonist. Study Selection/Data Extraction: This review included two phase 2, two phase 3, and one ongoing clinical trial evaluating the efficacy and/or safety of setmelanotide. Data Synthesis: Setmelanotide demonstrates statistically significant weight loss with at least a 10% decrease in body weight after 1 year and decreased appetite in phase 2 and phase 3 clinical trials. The most common adverse effects included injection site reaction (96%), skin hyperpigmentation (78%), nausea (56%), headache (41%), and diarrhea (37%). Place in Therapy: Setmelanotide is the first and only Food and Drug Administration–approved medication for the treatment of proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, and leptin receptor deficiency in patients with obesity. It may be used in children and adults who have received genetic testing and exhibited extreme obesity before age five. Setmelanotide is a daily subcutaneous injection and may be difficult to afford for patients. Conclusion: Setmelanotide is an effective treatment in patients with obesity and indicated genetic disorders.
- 17 February 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (4) , 320-333
A systematic review of the drug–drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies
Colchicine and statins are frequently co‐prescribed for prevention and treatment of cardiovascular diseases, auto‐inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P‐450 (CYP) 3A4 isozyme and P‐glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life‐threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin‐colchicine drug interaction and discuss related risk‐mitigation strategies. An electronic literature search was performed. Twenty‐one articles met the protocol to be included in the qualitative analysis: 18 case reports/series, 2 retrospective observational cohort studies, and 1 retrospective case‐control study. Thirty‐eight patients developed an adverse drug event (ADE) receiving statin‐colchicine combination therapy; 25 (66%) patients developed myopathy; 10 (26%) patients developed rhabdomyolysis, and three (8%) patients developed neuromyopathy. Over 70% of patients developed ADEs on simvastatin or atorvastatin, and 80% of studies reported moderate‐to‐high intensity statins. Colchicine dosing varied but ranged between 0.5 to 1.5 mg daily. Sixty‐two percent of patients in the case reports/series had comorbid renal disease. Seven studies (33% of all included studies) reported patients taking concomitant interacting medications at the CYP3A4 and/or P‐glycoprotein efflux pump. Seventeen studies (81% of all included studies) reported ADEs leading to hospitalization. A multivariate analysis from one case‐control study identified risk factors prognosticating myopathy ADEs in patients taking statin‐colchicine therapy: comorbid renal disease and/or cirrhosis, colchicine doses 1.2 mg daily or greater, and concomitant interacting medications. Clinicians must be cognizant that the statin‐colchicine drug interaction may lead to patient harm and thus should employ risk‐mitigation strategies for statin‐associated muscle symptoms. Future studies are warranted to validate clinically relevant risk factors that are strongly associated with the complications owing to the statin‐colchicine drug interaction.
- 17 February 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (4) , 320-333
A systematic review of the drug–drug interaction between statins and colchicine: Patient characteristics, etiologies, and clinical management strategies
Colchicine and statins are frequently co‐prescribed for prevention and treatment of cardiovascular diseases, auto‐inflammatory diseases, and gout. Both are substrates and inhibitors of the cytochrome P‐450 (CYP) 3A4 isozyme and P‐glycoprotein so that taken together, they represent a clinically significant interaction. Data suggest the interaction may be associated with potentially life‐threatening myopathies and rhabdomyolysis. The purposes of this systematic review (SR) were to gather and appraise evidence surrounding the statin‐colchicine drug interaction and discuss related risk‐mitigation strategies. An electronic literature search was performed. Twenty‐one articles met the protocol to be included in the qualitative analysis: 18 case reports/series, 2 retrospective observational cohort studies, and 1 retrospective case‐control study. Thirty‐eight patients developed an adverse drug event (ADE) receiving statin‐colchicine combination therapy; 25 (66%) patients developed myopathy; 10 (26%) patients developed rhabdomyolysis, and three (8%) patients developed neuromyopathy. Over 70% of patients developed ADEs on simvastatin or atorvastatin, and 80% of studies reported moderate‐to‐high intensity statins. Colchicine dosing varied but ranged between 0.5 to 1.5 mg daily. Sixty‐two percent of patients in the case reports/series had comorbid renal disease. Seven studies (33% of all included studies) reported patients taking concomitant interacting medications at the CYP3A4 and/or P‐glycoprotein efflux pump. Seventeen studies (81% of all included studies) reported ADEs leading to hospitalization. A multivariate analysis from one case‐control study identified risk factors prognosticating myopathy ADEs in patients taking statin‐colchicine therapy: comorbid renal disease and/or cirrhosis, colchicine doses 1.2 mg daily or greater, and concomitant interacting medications. Clinicians must be cognizant that the statin‐colchicine drug interaction may lead to patient harm and thus should employ risk‐mitigation strategies for statin‐associated muscle symptoms. Future studies are warranted to validate clinically relevant risk factors that are strongly associated with the complications owing to the statin‐colchicine drug interaction.
- 30 September 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 78 (Supplement) , S26-S32
Impact of antibiotic choice on readmission in adults experiencing an acute COPD exacerbation
The impact of antibiotic therapy in managing acute chronic obstructive pulmonary disease (COPD) exacerbations requiring hospitalization remains unclear. We conducted a study to assess the impact of antibiotic therapy on the rate of 30-day readmission after discharge from a hospital stay for an acute COPD exacerbation. Additional study outcomes analyzed included the effects of antibiotic therapy on hospital length of stay, in-hospital mortality, 90-day and 12-month readmission rates, and time to next COPD exacerbation. The study was an institutional review board–approved, retrospective, observational review of adult patients at a tertiary academic medical center. The medical records of patients 18 years of age or older who were hospitalized for an acute COPD exacerbation between January 2008 and December 2014 were evaluated. Included patients were stratified by receipt of guideline-appropriate, guideline-inappropriate, or no antibiotic therapy. Nonparametric data were analyzed using the Kruskal-Wallis test (nonparametric) and categorical data via χ 2 test, respectively. Three hundred twenty-five subjects were included; there were no significant differences in baseline characteristics in the 3 study groups. Sixty-eight percent of patients (n = 223) received antibiotics. The percentage of patients readmitted within 30 days did not differ between cohorts: 11.9% (appropriate therapy) vs 13.2% (nonappropriate therapy) vs 12.2% (no antibiotics) (P = 0.95 for all comparisons). Additionally, no detectable differences in 90-day or 12-month readmission rate, length of hospital day, or in-hospital mortality were found. However, a trend toward increased time to next COPD exacerbation was noted in those receiving antibiotics vs no antibiotics (352 days vs 192 days, P = 0.07). Treatment of COPD exacerbations with antibiotics did not impact readmission rates, length of hospital stay, in-hospital mortality, or time to next exacerbation. More investigation is warranted to assess the effect of antibiotics on time to next exacerbation, as well as comparative effectiveness between antibiotic classes.
- 30 September 2020
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 78 (Supplement) , S26-S32
Impact of antibiotic choice on readmission in adults experiencing an acute COPD exacerbation
The impact of antibiotic therapy in managing acute chronic obstructive pulmonary disease (COPD) exacerbations requiring hospitalization remains unclear. We conducted a study to assess the impact of antibiotic therapy on the rate of 30-day readmission after discharge from a hospital stay for an acute COPD exacerbation. Additional study outcomes analyzed included the effects of antibiotic therapy on hospital length of stay, in-hospital mortality, 90-day and 12-month readmission rates, and time to next COPD exacerbation. The study was an institutional review board–approved, retrospective, observational review of adult patients at a tertiary academic medical center. The medical records of patients 18 years of age or older who were hospitalized for an acute COPD exacerbation between January 2008 and December 2014 were evaluated. Included patients were stratified by receipt of guideline-appropriate, guideline-inappropriate, or no antibiotic therapy. Nonparametric data were analyzed using the Kruskal-Wallis test (nonparametric) and categorical data via χ 2 test, respectively. Three hundred twenty-five subjects were included; there were no significant differences in baseline characteristics in the 3 study groups. Sixty-eight percent of patients (n = 223) received antibiotics. The percentage of patients readmitted within 30 days did not differ between cohorts: 11.9% (appropriate therapy) vs 13.2% (nonappropriate therapy) vs 12.2% (no antibiotics) (P = 0.95 for all comparisons). Additionally, no detectable differences in 90-day or 12-month readmission rate, length of hospital day, or in-hospital mortality were found. However, a trend toward increased time to next COPD exacerbation was noted in those receiving antibiotics vs no antibiotics (352 days vs 192 days, P = 0.07). Treatment of COPD exacerbations with antibiotics did not impact readmission rates, length of hospital stay, in-hospital mortality, or time to next exacerbation. More investigation is warranted to assess the effect of antibiotics on time to next exacerbation, as well as comparative effectiveness between antibiotic classes.